MHD ANAS ALKHATIB: Open Payments
NPI 1528115326 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$453 in 23 payments from 11 companies in 2025. Trend: 2023 $1,261 · 2024 $1,699 · 2025 $453
Food & beverage: $453
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $97 |
| E.R. Squibb & Sons, L.L.C. | 3 | $64 |
| Noven Therapeutics, LLC | 3 | $61 |
| ViiV Healthcare Company | 3 | $49 |
| ABBVIE INC. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Neos Therapeutics, LP | 1 | $25 |
| Lundbeck LLC | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: INGREZZA, COBENFY, Xelstrym, CABENUVA, VRAYLAR, CAPLYTA, Metadate CD, REXULTI.
Industry payments across GA — which companies pay providers there.
